HER2-Low Breast Cancer: Pathological and Clinical Landscape

J Clin Oncol. 2020 Jun 10;38(17):1951-1962. doi: 10.1200/JCO.19.02488. Epub 2020 Apr 24.

Paolo Tarantino^{1

2}, Erika Hamilton³, Sara M Tolaney⁴, Javier Cortes^{5

6}, Stefania Morganti^{1

2}, Emanuela Ferraro^{1

2}, Antonio Marra^{1

2}, Giulia Viale^{1

2}, Dario Trapani^{1

2}, Fatima Cardoso⁷, Frédérique Penault-Llorca^{8

9}, Giuseppe Viale^{1

2}, Fabrice Andrè¹⁰, Giuseppe Curigliano^{1

2}

¹ European Institute of Oncology IRCCS, Milan, Italy.
² University of Milan, Milan, Italy.
³ Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.
⁴ Dana-Farber Cancer Institute, Boston, MA.
⁵ IOB Institute of Oncology, Quiron Group, Madrid and Barcelona, Spain.
⁶ Vall d'Hebron Institute of Oncology, Barcelona, Spain.
⁷ Breast Unit Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.
⁸ Jean Perrin Comprehensive Cancer Center, Department of Pathology and Tumor Biology, Centre Jean Perrin, Clermont-Ferrand, France.
⁹ UMR INSERM 1240 IMoST, Université Clermont Auvergne, Villejuif, France.
¹⁰ Department of Medical Oncology, Gustave Roussy, Villejuif, France.

No abstract available

Publication types